Healthcare shares are mixed in pre-market trade. Repligen
) says it received a $1 million milestone payment from Pfizer (
) under the terms of the companies' exclusive worldwide licensing
agreement for the development of compounds to treat spinal muscular
atrophy. RGEN is flat in pre-market trade.
This first milestone payment was triggered by completion of
specific program activities and coincides with the successful
completion of all transition obligations by RGEN.
And, Rockwell Medical (
) surged nearly 11% in pre-market trading to $6.10 after saying its
iron-delivery drug SFP for the treatment of iron deficiency in
chronic kidney disease patients receiving hemodialysis met primary
and key secondary endpoints in a phase 3 efficacy study.
In dialysis patients not receiving intravenous iron, SFP
effectively delivered it via dialysate. The drug also appears safe
and effective as an iron replacement therapy that maintains
hemoglobin levels without increasing iron stores.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.